Post by Division of Nuclear Medicine (Medical University of Vienna)

New Publication Highlight | Radioligand Therapy in Early-Stage Prostate Cancer 📑   We are pleased to share our latest publication in the European Journal of Nuclear Medicine and Molecular Imaging (February 2026): https://lnkd.in/dwDxjDf4 🔍 Key findings at a glance:   1. Significant PSA decline observed after [¹⁷⁷Lu]Lu-PSMA-RLT in therapy-naïve mHSPC patients; 2. 62.5% of patients achieved ≥50% PSA reduction; 3. Median PSA progression-free survival reached 24.6 months in responders; 4. Baseline total tumor volume (TTV) and metastatic burden predicted ADT-free and any-therapy-free survival; 5. Excellent tolerability with no severe treatment-related adverse events.   📌 Notably, PSMA PET–derived SUV parameters did not differentiate responders from non-responders, suggesting a more homogeneous tumor biology in treatment-naïve mHSPC patients. This study provides important insights into the potential role of [¹⁷⁷Lu]Lu-PSMA-RLT earlier in the disease course, while highlighting the need for prospective trials to further define patient selection and clinical benefit. Congratulations to the author team for this valuable contribution to translational and clinical nuclear medicine! Ilva Kristiāna Langrate, Heidemarie Ofner, Elisabeth Kretschmer-Chott, Holger Einspieler, Oana Kulterer, Stefan Schmitl, Lukas Nics, Shahrokh Shariat, MD, Marcus Hacker, Sazan Rasul, Gero Kramer #NuclearMedicine #RadioligandTherapy #Lu177 #PSMA #ProstateCancer #Theranostics #ClinicalResearch #EJNMMI #Radiopharmaceuticals #RadionuclideTherapy #HybridImaging #PET #PETCT #PSMAPET #ClinicalImaging #Lutetium177 #LuPSMA #PSMATherapy #TargetedTherapy #PrecisionMedicine #PersonalizedMedicine #TargetedRadiotherapy